These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 18803997

  • 21. Single-pill combination of amlodipine and valsartan in the management of hypertension.
    Flack JM, Hilkert R.
    Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
    [Abstract] [Full Text] [Related]

  • 22. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies.
    Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D.
    J Am Board Fam Med; 2007 Aug; 20(1):72-80. PubMed ID: 17204738
    [Abstract] [Full Text] [Related]

  • 23. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
    Chrysant SG.
    Postgrad Med; 2011 Nov; 123(6):21-31. PubMed ID: 22104451
    [Abstract] [Full Text] [Related]

  • 24. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD, Mion D, Rocha JC, Kohlmann O, Gomes MA, Saraiva JF, Amodeo C, Filho BL.
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [Abstract] [Full Text] [Related]

  • 25. Re: Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.
    Vivencio B.
    Curr Med Res Opin; 2009 Sep; 25(9):2267-8; author reply 2268-9. PubMed ID: 19630488
    [No Abstract] [Full Text] [Related]

  • 26. Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).
    Tardif JC, Curnew GP, Leclerc JM, Rehel B.
    Can J Clin Pharmacol; 2008 Sep; 15(2):e177-87. PubMed ID: 18515919
    [Abstract] [Full Text] [Related]

  • 27. Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data.
    Grant RW, Singer DE, Meigs JB.
    Clin Ther; 2005 Jun; 27(6):773-81. PubMed ID: 16117984
    [Abstract] [Full Text] [Related]

  • 28. Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial.
    Ruilope LM, Zanchetti A.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S8-11. PubMed ID: 16986228
    [Abstract] [Full Text] [Related]

  • 29. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
    Saito I, Saruta T, ADVANCE-Combi Study Group.
    Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
    [Abstract] [Full Text] [Related]

  • 30. Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
    Kondrack R, Mohiuddin S.
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1125-34. PubMed ID: 19689218
    [Abstract] [Full Text] [Related]

  • 31. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence.
    Balu S, Simko RJ, Quimbo RM, Cziraky MJ.
    Curr Med Res Opin; 2009 Nov; 25(11):2765-75. PubMed ID: 19785511
    [Abstract] [Full Text] [Related]

  • 32. [Medication of the month. Exforge HCT: combination of amlodipine besylate, valsartan and hydrochlorothiazide in a single tablet].
    Lancellotti P.
    Rev Med Liege; 2010 Nov; 65(7-8):471-5. PubMed ID: 20857707
    [Abstract] [Full Text] [Related]

  • 33. Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs.
    Machnicki G, Ong SH, Chen W, Wei ZJ, Kahler KH.
    Curr Med Res Opin; 2015 Dec; 31(12):2287-96. PubMed ID: 26397178
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study.
    Saito I, Fujikawa K, Saruta T, ADVANCE-Combi Study Group.
    Hypertens Res; 2008 Jul; 31(7):1399-405. PubMed ID: 18957811
    [Abstract] [Full Text] [Related]

  • 35. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
    Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimský J, Zanchetti A, VALUE Trial Investigators.
    J Hypertens; 2006 Jul; 24(7):1405-12. PubMed ID: 16794491
    [Abstract] [Full Text] [Related]

  • 36. Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany.
    Breitscheidel L, Ehlken B, Kostev K, Oberdiek MS, Sandberg A, Schmieder RE.
    J Med Econ; 2012 Jul; 15(1):155-65. PubMed ID: 22035215
    [Abstract] [Full Text] [Related]

  • 37. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
    Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, VALUE Trial Group.
    J Hypertens; 2008 Mar; 26(3):403-11. PubMed ID: 18300848
    [Abstract] [Full Text] [Related]

  • 38. Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension.
    Robertson TA, Cooke CE, Wang J, Shaya FT, Lee HY.
    Am J Manag Care; 2008 Nov; 14(11):710-6. PubMed ID: 18999905
    [Abstract] [Full Text] [Related]

  • 39. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
    Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimsky J, Zanchetti A.
    Blood Press; 2008 Nov; 17(3):170-7. PubMed ID: 18608200
    [Abstract] [Full Text] [Related]

  • 40. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S.
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.